Skip to main content


Generic name: tixagevimab and cilgavimab
Dosage form: intramuscular injection
Drug class: Antiviral combinations

Medically reviewed by Philip Thornton, DipPharm. Last updated on Jul 12, 2023.

UPDATE: FDA Announces Evusheld is Not Currently Authorized for Emergency Use in the U.S.
January 26, 2023 -- Evusheld is not currently authorized in any U.S. region due to the high frequency of circulating SARS-CoV-2 variants that are non-susceptible to Evusheld. Therefore, Evusheld may not be administered for pre-exposure prophylaxis for prevention of COVID-19 under the Emergency Use Authorization until further notice by the Agency.

What is Evusheld?

Evusheld is an investigational medication that packages together in one carton two separate monoclonal antibodies - tixagevimab and cilgavimab.

Tixagevimb and cilgavimab are human immunoglobulin G1 (IgG1κ) monoclonal antibodies produced in Chinese hamster ovary (CHO) cells using recombinant DNA technology. They are SARS-CoV-2 spike protein-directed attachment inhibitors.

The monoclonal antibodies in Evusheld work by binding to the spike protein on SARS-CoV-2, the virus that causes COVID-19. This blocks the virus from being able to bind to ACE2 receptors, which is what enables the virus to invade your cells.

Evusheld is still being studied and is unapproved. It is, however, authorized for use by the US Food and Drug Administration (FDA) under its Emergency Use Authorization (EUA) program. It was first authorized for use in the US in December 2021.

What is Evusheld used for?

Evusheld is prescribed for pre-exposure prophylaxis for prevention of COIVD-19 in adults and adolescents 12 years of age and older who weigh at least 88 pounds (40 kg).

It is for use in people who are not currently infected with SARS-CoV-2 and who have not had recent close contact with someone who is infected with the virus and:

Medical conditions or treatments that may result in moderate-to-severe immune system compromise and an inadequate immune response to a COVID-19 vaccine include but are not limited to:

Evusheld is not authorized for use in individuals:

Pre-exposure prophylaxis with this medication is not a substitute for vaccination for those who are recommended to get vaccinated. You should still receive a COVID-19 vaccine if it is recommended for you.

Important information

It is possible that Evusheld may reduce your body’s immune response to a COVID-19 vaccine. If you have received a COVID-19 vaccine, you should wait at least 2 weeks to receive Evusheld.

Who should not receive Evusheld?

Do not receive Evusheld if you have a severe allergic reaction to tixagevimab or cilgavimab or any of the other ingredients in this medication. See below for a complete list of ingredients.

What should I tell my doctor before receiving Evusheld?

How should I receive Evusheld?

What happens if I miss a dose?

It is recommended to receive Evusheld every six months if ongoing protection is required. Talk to your healthcare provider if you are due for another dose of Evusheld.

Dosing information

The dosage of Evusheld for emergency use is:

See the Full Prescribing Information for further information about Evusheld dosing.

What are the side effects of Evusheld?

Possible side effects of Evusheld include:

The side effects of getting any medicine by intramuscular injection may include:

These are not all the possible side effects of this medication, which has not been given to a lot of people. Evusheld is still being studied so it is possible that all of the risks are not known at this time. Serious and unexpected side effects may happen.

Contact your healthcare provider if you have any side effects that bother you or do not go away. Report side effects to FDA MedWatch at or call 1-800-FDA-1088 or call AstraZeneca at 1-800-236-9933.


Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Pregnancy and breastfeeding

Tell your healthcare provider if you are pregnant or plan to become pregnant. It is not known if Evusheld will affect your unborn baby. Evusheld should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus.

Tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not know whether this medication passes into breastmilk or affects breastfed babies. Talk to your healthcare provider about the best way to feed your baby if you receive Evusheld.


What are the ingredients in Evusheld?

Active ingredients: tixagevimab is the active ingredient in one vial and cilgavimab is the active ingredient in the other.

Inactive ingredients: Each vial contains L- histidine, L- histidine hydrochloride monohydrate, polysorbate 80, sucrose, water.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.